Hercules Capital, Inc. (HTGC) 2021 10-K Summary
Business Context and Reporting Period
Company: Hercules Capital, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2021
Business Model: Hercules is an internally managed, non-diversified Business Development Company (BDC) and Regulated Investment Company (RIC). It focuses on providing senior secured loans, structured debt with warrants, and equity investments to high-growth, venture capital-backed companies in technology, life sciences, and sustainable/renewable technology sectors.
Key Financial Metrics
| Metric | 2021 | 2020 |
|---|---|---|
| Total Investment Portfolio (Fair Value) | $2.43 billion | $2.35 billion |
| Net Investment Income | $150.0 million | $157.1 million |
| Net Realized Gains (Losses) | $20.9 million | ($56.1 million) |
| Net Change in Unrealized Appreciation | $3.3 million | $126.2 million |
| Net Increase in Net Assets from Operations | $174.2 million | $227.3 million |
| Net Assets (Equity) | $1.31 billion | $1.29 billion |
| Net Asset Value (NAV) per Share | $11.22 | $11.26 |
| Total Debt Outstanding | $1.25 billion | $1.29 billion |
| Asset Coverage Ratio (Excl. SBA) | 218.9% | 204.6% |
| Weighted Average Core Yield | 11.4% | 11.6% |
| Weighted Average Effective Yield | 12.9% | 12.9% |
Material Changes vs. Prior Period
- Portfolio Composition: The portfolio grew slightly to $2.43 billion. "Drug Discovery & Development" became the largest sector at 39.7% of the portfolio (up from 32.2%), while "Software" decreased to 24.1% (down from 33.1%).
- Realized Gains: A significant turnaround occurred in realized gains, moving from a net loss of $56.1 million in 2020 to a net gain of $20.9 million in 2021. This was driven by sales of DoorDash, Palantir, and TransMedics, offset by write-offs of Intent Media and Solar Spectrum.
- Unrealized Appreciation: Net unrealized appreciation dropped significantly from $126.2 million in 2020 to $3.3 million in 2021, reflecting market volatility and valuation adjustments.
- Debt Management: The company refinanced and retired significant debt, including the full repayment of $364.2 million in principal related to 2025, 2027, and 2028 Asset-Backed Notes. New issuances included $375.0 million in notes (March 2026 B Notes and September 2026 Notes).
- Operating Expenses: Total net operating expenses remained relatively flat at $131.0 million (2021) vs. $130.1 million (2020), despite an increase in employee compensation due to higher headcount and variable pay.
Guidance, Outlook, and Risks
- Outlook: Management continues to monitor the impact of the COVID-19 pandemic, noting that while economic recovery is positive, new variants and supply chain disruptions remain risks. The company maintains ample liquidity ($627.7 million available) to support near-term capital requirements.
- Distributions: The Board declared a Q4 2021 cash distribution of $0.33 per share and a supplemental distribution of $0.60 per share (paid in four quarterly installments). The company targets distributing 90-100% of taxable income.
- Key Risks:
- Concentration Risk: Heavy exposure to the "Drug Discovery & Development" sector (39.7%) and "Software" (24.1%).
- Interest Rate Risk: 94.0% of the debt portfolio is floating-rate, making income sensitive to rate changes, though most loans have floors.
- Liquidity and Leverage: As a BDC, the company is subject to asset coverage requirements (minimum 150%). Failure to meet these could restrict distributions or borrowing.
- LIBOR Transition: Approximately 21.3% of debt investments are LIBOR-based; the company is transitioning to SOFR fallbacks.
Investor Verification Checklist
- Portfolio Valuation: Verify the fair value methodology for Level 3 assets (93.6% of total assets), which relies on Board determination rather than market quotes.
- Debt Maturity Wall: Review the schedule of debt maturities, noting $380.0 million due within one year (though some were refinanced in subsequent events).
- Unfunded Commitments: Confirm the company's ability to fund $286.8 million in unfunded commitments without straining liquidity.
- Non-Accrual Status: Monitor the 1.0% of the portfolio on non-accrual status ($24 million) for potential credit losses.
- Adviser Subsidiary: Review the allocation of expenses ($5.0 million) and potential conflicts of interest with the newly formed Adviser Subsidiary managing external funds.